Top Story Today
The $11.3 Billion Bet on Picks and Shovels
Merck KGaA is paying $11.3 billion in cash for Bio-Techne, a company most people outside a lab have never heard of. Bio-Techne makes the proteins, antibodies, and analytical tools that drug developers depend on every single day: over 500,000 products generating $1.2 billion in annual revenue. The deal is the largest life sciences tools acquisition of 2026 and gives Merck deep exposure to the booming cell and gene therapy tools market, spatial biology, and precision diagnostics. At 23.2x EBITDA (or about 17.5x after projected cost synergies), Wall Street called the price full but fair.
Why it matters: The tools and infrastructure layer of biotech is consolidating fast. With global life sciences M&A hitting $240 billion in 2025, the race to become the one-stop-shop supplier for drug discovery is reshaping the entire industry supply chain.
Read more →Deals and M&A
Gilead Drops $5 Billion on a German ADC Factory
Gilead is paying up to $5 billion ($3.15 billion upfront) for Tubulis, a Munich-based startup with a modular platform for building antibody-drug conjugates. The lead asset, TUB-040, posted a 59% response rate in platinum-resistant ovarian cancer. This is Gilead's third major acquisition of 2026, pushing its yearly M&A tab past $12.7 billion as it pivots hard from HIV into oncology.
Read more →AstraZeneca Pays $200M for a Chinese COPD Drug With $2.1B Upside
AstraZeneca licensed TQC3721, a dual PDE3/4 inhibitor for COPD, from Sino Biopharmaceutical for $200 million upfront and up to $1.9 billion in milestones. Early Phase 2 data showed meaningful lung function improvement. The deal highlights China's emergence as a top-tier source of innovative drugs, with cross-border licensing deals hitting $136 billion in total value in 2025.
Read more →Clinical and Regulatory
Europe Revokes Amgen's Tavneos Over Forged Trial Data
Europe's drug regulator recommended pulling Amgen's Tavneos after investigators found incorrect and misleading data in the pivotal trial run by ChemoCentryx (which Amgen bought for $3.7 billion), with endpoint results manipulated after unblinding, flipping the pivotal trial from non-significant to statistically significant. The FDA has separately proposed U.S. withdrawal. It's one of the rarest regulatory actions in modern pharma and a cautionary tale for every company doing M&A on single-trial assets.
Read more →Congress Wants Answers on Merck and AbbVie's China Military Hospital Trials
A House committee sent letters to Merck and AbbVie demanding details on hundreds of clinical trials run at Chinese military hospitals and in Xinjiang. Merck has sponsored roughly 224 studies in China since 2005, with at least 31 in Xinjiang. The probe has since expanded to Lilly, Pfizer, and BMS, raising questions about whether China-generated data could face restrictions in future U.S. drug approvals.
Read more →Science and Financings
Two Startups Claim They Made Human Gametes in a Lab. From Scratch.
Paterna Biosciences says it grew functional human sperm from testicular stem cells and used them to create early embryos. Separately, Conception Biosciences generated early-stage human egg cells from a simple blood draw. Neither result has been peer-reviewed yet, but if the science holds up, the future of fertility treatment (and human reproduction itself) just got radically rewritten.
Read more →Gene Editing Breaks a Two-Year IPO Drought
Scribe Therapeutics priced its IPO at $15 per share (top of range), raising $129 million in the first gene-editing public offering since early 2024. Sanofi bought in alongside public investors. The Berkeley spinout is developing an epigenetic silencing approach to permanently lower cholesterol without cutting DNA.
Read more →